Rethinking Clinical Trials

DECEMBER 12, 2023

Tags #pctGR, @Collaboratory1 The post Grand Rounds December 8, 2023: A Pragmatic Randomized Trial of the Jumpstart Intervention to Promote Communication about Goals of Care for Hospitalized Patients with Serious Illness (Ruth Engelberg, PhD; Erin Kross, MD; Robert Lee, MD, MS) appeared first on Rethinking Clinical Trials.

Trials 130

Trials Medicine Clinical Trials Clinical Trials 130

Rethinking Clinical Trials

APRIL 18, 2023

The 5 trials, RECOVER-VITAL, RECOVER-AUTONOMIC, RECOVER-SLEEP, RECOVER-NEURO, and RECOVER-ENERGIZE, will enroll about 2,600 total participants, and each trial will include between 25-100 sites. The first trial will begin enrolling in July 2023. It seems the most severely affected people came from the early waves of COVID.

Clinical Trials 219

Clinical Trials Clinical Trials Trials Immune Response 219

pharmaphorum

AUGUST 21, 2022

There’s no word yet on its pricing, but for comparison Spravato was launched with an annual price tag of around $32,400, which the Institute for Clinical and Economic Review (ICER) concluded was around 25% to 52% too high to be cost effective. Photo by Sydney Sims on Unsplash.

Drugs 89

Drugs FDA Approval Production Marketing 89

Delveinsight

DECEMBER 3, 2020

It has been speculated that modifications to the epigenome drive cell ageing, especially a process known as DNA methylation, by which methyl groups are tagged onto DNA. Shinya Yamanaka discovered that the factors could alter the epigenome, and in that way modify mature cells back to a stem cell-like state.

Gene Therapy 52

Gene Therapy Gene Antibody Research 52

The Pharma Data

MAY 15, 2021

It records where you’ve been… How long you’ve walked for… How many steps you’ve taken… How many calories you’ve burned… How well you’re sleeping and so on. It tracks your sleep patterns so you can see if you’re getting enough quality rest so you wake up energized.

Production 52

Production Containment Medicine Vaccination 52

Pharmaceutical Technology

NOVEMBER 30, 2022

The company’s weight loss drug Saxenda (liraglutide) won an approval for chronic weight management in December 2014, and Wegovy (semaglude) got the same tag in 2021. There are also improvements in blood pressure and sleep apnea,” says Papamargaritis. Novo Nordisk is another company leading the charge in this field. compared to a 5.1%

Drugs 264

Drugs Manufacturing Hormones Contract Manufacturing 264

Pharmaceutical Technology

NOVEMBER 30, 2022

The company’s weight loss drug Saxenda (liraglutide) won an approval for chronic weight management in December 2014, and Wegovy (semaglude) got the same tag in 2021. There are also improvements in blood pressure and sleep apnea,” says Papamargaritis. Novo Nordisk is another company leading the charge in this field. compared to a 5.1%

Drugs 246

Drugs Manufacturing Hormones Contract Manufacturing 246